Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Multiple sclerosis

Breakthrough Study Offers New Hope for Multiple Sclerosis Treatment

Recent advancements in multiple sclerosis (MS) treatment show promise with a novel approach combining cell therapy and an approved drug. Researchers at the Germans Trias i Pujol Research Institute are exploring the use of tolerogenic dendritic cells (tolDCs) derived from patients’ immune systems to restore balance without compromising natural defenses. This innovative study, published in the Journal of Clinical Investigation, highlights the potential to enhance treatment outcomes by integrating personalized cell therapy with existing medications.

CD8 T Cells Identified as Key Indicators in Early Multiple Sclerosis Onset

Recent research highlights the crucial role of CD8-positive T cells in the early stages of multiple sclerosis (MS). Led by PD Dr. Lisa Ann Gerdes, this study, published in Science Immunology, utilized identical twins to uncover immune cell changes that may signal MS onset. The findings suggest that alterations in CD8 T cells could serve as early indicators of the disease, paving the way for new diagnostic and therapeutic strategies. Understanding these immune responses is vital for early intervention in MS, a condition that can lead to severe neurological deficits.

Probiotic Breakthrough in MS Management

Discover the groundbreaking study on a juice-based probiotic’s ability to inhibit toxin-producing bacteria linked to multiple sclerosis (MS). Learn how this innovative approach offers a natural and potentially more tolerable option for managing MS symptoms, providing hope for patients seeking alternative treatments.

Sydney Neuroimaging Centre Secures Funding for AI-Powered Brain Disease Analysis Software

Sydney Neuroimaging Analysis Centre has secured significant government funding and regulatory approval for its innovative AI-powered software to analyze and monitor brain diseases. The A$3.75 million funding from ANDHealth+ will advance the commercialization of its AI-enabled medical imaging software, iQ-solutions, offering precise analysis of brain structures from MRI scans. SNAC is also developing tools like Torana and VeriScout for medical scan management and automatic detection of cerebral hemorrhage. With global market clearances, SNAC is set to make a significant impact in the $250 million brain image analysis market.

Woman Battles Multiple Sclerosis and Parkinson’s Disease with Resilience

Read about Emma Tinkler’s inspiring journey living with both multiple sclerosis and Parkinson’s disease, showcasing resilience and strength in the face of adversity. Despite facing constant monitoring and medication, Emma’s determination to lead a fulfilling life is truly inspiring.

World MS Day: Uniting the Global MS Community

Learn about the significance of World Multiple Sclerosis Day, established by the MSIF to raise awareness about multiple sclerosis. Discover how this day unites the global MS community, advocates for change, and emphasizes the importance of early diagnosis. Explore the impact of MS on individuals worldwide and the ongoing efforts in research, clinical advancements, and community support for those living with the disease.

Cionic’s Neural Sleeve Shows Positive Impact on Multiple Sclerosis Patients in Real-World Study

Discover the positive impact of Cionic’s Neural Sleeve technology on patients with multiple sclerosis. A recent study highlighted improvements in walking challenges, showcasing enhanced foot and ankle mobility. CEO Jeremiah Robison emphasizes the importance of tailored technology for neurologic conditions, offering hope for improved quality of life.

Groundbreaking Study Shows Early High-Efficacy Therapies Improve Outcomes for Pediatric MS

Groundbreaking global study reveals that early and aggressive treatment with high-efficacy therapies can significantly improve outcomes for children with multiple sclerosis (MS). Research emphasizes the importance of administering high-efficacy disease-modifying therapies to pediatric MS patients early in their diagnosis to prevent the onset of significant disability. Study analyzed data from over 5,000 individuals diagnosed with MS during childhood over the past 30 years, drawing from international registries and national databases. Findings offer hope for improved treatment strategies for pediatric MS, potentially reshaping the approach to managing the condition in young patients.

Study Finds Environmental Chemicals Impact Oligodendrocyte Development

A recent study published in Nature Neuroscience has found that environmental chemicals can impact the development of oligodendrocytes, crucial for neurodevelopment. The study identified two classes of chemicals, quaternary compounds and organophosphate flame retardants, that disrupt oligodendrocyte development through distinct mechanisms. The research also demonstrated the impairment of oligodendrocyte development in mice and human 3D organoid models, as well as associations with adverse neurodevelopmental outcomes. This highlights the need for further investigation into the potential impacts of these environmental chemicals on human health.

David Osmond Opens Up About Living with Multiple Sclerosis

David Osmond, a member of the Osmond family, opens up about his personal journey with multiple sclerosis, shedding light on the challenges and triumphs he has encountered. His candid discussion provides valuable insights into the daily realities of living with the disease, offering hope and encouragement to others grappling with similar circumstances. Osmond’s willingness to share his story serves as a source of inspiration, highlighting the resilience and determination exhibited by individuals navigating the complexities of chronic illness.